Interaction between NADPH-oxidase and Rho-kinase in angiotensin II-induced microglial activation

GLIA

Volumn 63, Issue 3, 2015, Pages 466-482

  Rodriguez Perez, Ana I ^a,b   Borrajo, Ana ^a,b   Rodriguez Pallares, Jannette ^a,b   Guerra, Maria J ^a,b   Labandeira Garcia, Jose L ^a,b  

^a Universidade de Santiago de Compostela and Instituto de Investigación Sanitaria de Santiago de Compostela   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Angiotensin; Microglia; NADPH oxidase; Neuroinflammation; Parkinson; Rho

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN P47; PROTEIN P67; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SUPEROXIDE; TRANSCRIPTION FACTOR RELA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL MOTILITY; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVATION; ENZYME ACTIVITY; MALE; MESENCEPHALON; MICROGLIA; MICROGLIAL CELL CULTURE; NONHUMAN; PHAGOCYTOSIS; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RAT; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; UPREGULATION; YOUNG ADULT; ANIMAL; CELL CULTURE; CELL LINE; ENZYMOLOGY; IMMUNOLOGY; METABOLISM; MOUSE; SPRAGUE DAWLEY RAT;

ANGIOTENSIN II; ANIMALS; CELL LINE; CELLS, CULTURED; MALE; MICE; MICROGLIA; NADPH OXIDASE; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RHO-ASSOCIATED KINASES; SUBSTANTIA NIGRA; SUPEROXIDES;

EID: 84920936666     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.22765     Document Type: Article

References (83)

1. Babior B. 1999. NADPH oxidase: An update. Blood 93:1464-1476.
2. Babior BM. 2004. NADPH oxidase. Curr Opin Immunol 16:42-47.
3. Barcia C, Ros CM, Annese V, Carrillo-de Sauvage MA, Ros-Bernal F, Gómez A, Yuste JE, Campuzano CM, de Pablos V, Fernandez-Villalba E, Herrero MT. 2012. ROCK/Cdc42-mediated microglial motility and gliapse formation lead to phagocytosis of degenerating dopaminergic neurons in vivo. Sci Rep 2:809.
4. Bernhart E, Kollroser M, Rechberger G, Reicher H, Heinemann A, Schratl P, Hallström S, Wintersperger A, Nusshold C, DeVaney T, Zorn-Pauly K, Malli R, Graier W, Malle E, Sattler W. 2010. Lysophosphatidic acid receptor activation affects the C13NJ microglia cell line proteome leading to alterations in glycolysis, motility, and cytoskeletal architecture. Proteomics 10:141-158.
5. Borrajo A, Rodriguez-Perez AI, Villar-Cheda B, Guerra MJ, Labandeira-Garcia JL. 2014a. Inhibition of the microglial response is essential for the neuroprotective effects of Rho-kinase inhibitors on MPTP-induced dopaminergic cell death. Neuropharmacology 85C:1-8.
6. Borrajo A, Rodriguez-Perez AI, Diaz-Ruiz C, Guerra MJ, Labandeira-Garcia JL. 2014b. Microglial TNF-α Mediates enhancement of dopaminergic degeneration by brain angiotensin. Glia 62:145-157.
7. Budzyn K, Marley PD, Sobey CG. 2006. Targeting Rho and Rho-kinase in the treatment of cardiovascular disease. Trends Pharmacol Sci 27:97-104.
8. Calleros L, Lasa M, Rodríguez-Alvarez FJ, Toro MJ, Chiloeches A. 2006. RhoA and p38 MAPK mediate apoptosis induced by cellular cholesterol depletion. Apoptosis 11:1161-1173.
9. Chen M, Liu A, Ouyang Y, Huang Y, Chao X, Pi R. 2013. Fasudil and its analogs: A new powerful weapon in the long war against central nervous system disorders? Expert Opin Investig Drugs 22:537-545.
10. Chhor V, Le Charpentier T, Lebon S, Oré MV, Celador IL, Josserand J, Degos V, Jacotot E, Hagberg H, Sävman K, Mallard C, Gressens P, Fleiss B. 2013. Characterization of phenotype markers and neuronotoxic potential of polarised primary microglia in vitro. Brain Behav Immun 32:70-85.
11. Choi DH, Cristóvão AC, Guhathakurta S, Lee J, Joh TH, Beal MF, Kim YS. 2012b. NADPH oxidase 1-mediated oxidative stress leads to dopamine neuron death in Parkinson's disease. Antioxid Redox Signal 16:1033-1045.
12. Choi SH, Aid S, Kim HW, Jackson SH, Bosetti F. 2012a. Inhibition of NADPH oxidase promotes alternative and anti-inflammatory microglial activation during neuroinflammation. J Neurochem 120:292-301.
13. Detmers PA, Zhou D, Polizzi E, Thieringer R, Hanlon WA, Vaidya S, Bansal V. 1998. Role of stress-activated mitogen-activated protein kinase (p38) in beta 2-integrin-dependent neutrophil adhesion and the adhesion-dependent oxidative burst. J Immunol 161:1921-1929.
14. Ganong WF. 1994. Origin of the angiotensin II secreted by cells. Proc Soc Exp Biol Med 205:213-219.
15. Garrido-Gil P, Rodriguez-Pallares J, Dominguez-Meijide A, Guerra MJ, Labandeira-Garcia JL. 2013a. Brain angiotensin regulates iron homeostasis in dopaminergic neurons and microglial cells. Exp Neurol 250:384-396.
16. Garrido-Gil P, Valenzuela R, Villar-Cheda B, Lanciego JL, Labandeira-Garcia JL. 2013b. Expression of angiotensinogen and receptors for angiotensin and prorenin in the monkey and human substantia nigra: An intracellular renin-angiotensin system in the nigra. Brain Struct Funct 218:373-388.
17. Ghosh A, Kanthasamy A, Joseph J, Anantharam V, Srivastava P, Dranka BP, Kalyanaraman B, Kanthasamy AG. 2012. Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson's disease. J Neuroinflammation 9:241.
18. Gilmore TD. 2006. Introduction to NF-kappaB: Players, pathways, perspectives. Oncogene 25:6680-6684.
19. González-Hernández T, Cruz-Muros I, Afonso-Oramas D, Salas-Hernandez J, Castro-Hernandez J. 2010. Vulnerability of mesostriatal dopaminergic neurons in Parkinson's disease. Front Neuroanat 4:140.
20. Grammatopoulos TN, Jones SM, Ahmadi FA, Hoover BR, Snell LD, Skoch J, Jhaveri VV, Poczobutt AM, Weyhenmeyer JA, Zawada WM. 2007. Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra. Mol Neurodegener 2:1.
21. Greenwood J, Walters CE, Pryce G, Kanuga N, Beraud E, Baker D, Adamson P. 2003. Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J 17:905-907.
22. Griendling KK, Sorescu D, Ushio-Fukai M. 2000. NADPH oxidase. Role in cardiovascular biology and disease. Circulation Res 86:494-501.
23. Heyworth PG, Curnutte JT, Nauseef WM, Volpp BD, Pearson DW, Rosen H, Clark RA. 1991. Neutrophil nicotinamide adenine dinucleotide phosphate oxidase assembly. Translocation of p47-phox and p67-phox requires interaction between p47-phox and cytochrome b558. J Clin Invest 87:352-356.
24. Higashi M, Shimokawa H, Hattori T, Hiroki J, Mukai Y, Morikawa K, Ichiki T, Takahashi S, Takeshita A. 2003. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: Effect on endothelial NAD(P)H oxidase system. Circ Res 93:767-775.
25. Hiroki J, Shimokawa H, Higashi M, Morikawa K, Kandabashi T, Kawamura N, Kubota T, Ichiki T, Amano M, Kaibuchi K, Takeshita A. 2004. Inflammatory stimuli upregulate Rho-kinase in human coronary vascular smooth muscle cells. J Mol Cell Cardiol 7:537-546.
26. Hirsch EC, Vyas S, Hunot S. 2012. Neuroinflammation in Parkinson's disease. Parkinsonism Relat Disord 18 Suppl 1:S210-212.
27. Hong H, Zeng JS, Kreulen DL, Kaufman DI, Chen AF. 2006. Atorvastatin protects against cerebral infarction via inhibition of NADPH oxidase-derived superoxide in ischemic stroke. Am J Physiol Heart Circ Physiol 291:H2210-2215.
28. Honing H, van den Berg TK, van der Pol SM, Dijkstra CD, van der Kammen RA, Collard JG, de Vries HE. 2004. RhoA activation promotes transendothelial migration of monocytes via ROCK. J Leukoc Biol 5:523-528.
29. Joglar B, Rodriguez-Pallares J, Rodriguez-Perez AI, Rey P, Guerra MJ, Labandeira-Garcia JL. 2009. The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: Relevance to progression of the disease. J Neurochem 109:656-669.
30. Katoh H, Aoki J, Ichikawa A, Negishi M. 1998. p160 RhoA-binding kinase ROKalpha induces neurite retraction. J Biol Chem 273:2489-2492.
31. Labandeira-Garcia JL, Rodriguez-Pallares J, Dominguez-Meijide A, Valenzuela R, Villar-Cheda B, Rodríguez-Perez AI. 2013. Dopamine-angiotensin interactions in the basal ganglia and their relevance for Parkinson's disease. Mov Disord 28:1337-1342.
32. Labandeira-Garcia JL, Rodriguez-Pallares J, Rodríguez-Perez AI, Garrido-Gil P, Villar-Cheda B, Valenzuela R, Guerra MJ. 2012. Brain angiotensin and dopaminergic degeneration: Relevance to Parkinson's disease. Am J Neurodegener Dis 1:226-244.
33. Li JM, Shah AM. 2003. Mechanism of endothelial cell NADPH oxidase activation by angiotensin II. Role of the p47phox subunit. J Biol Chem 278:12094-12100.
34. Li M, Zhuan L, Wang T, Rao K, Yang J, Yang J, Quan W, Liu J, Ye Z. 2012. Apocynin improves erectile function in diabetic rats through regulation of NADPH oxidase expression. J Sex Med 9:3041-3050.
35. Lull ME, Block ML. 2010. Microglial activation and chronic neurodegeneration. Neurotherapeutics 7:354-365.
36. Maldonado PD, Molina-Jijón E, Villeda-Hernández J, Galván-Arzate S, Santamaría A, Pedraza-Chaverrí J. 2010. NAD(P)H oxidase contributes to neurotoxicity in an excitotoxic/prooxidant model of Huntington's disease in rats: Protective role of apocynin. J Neurosci Res 88:620-629.
37. Mattson MP, Maudsley S. 2009. Live longer sans the AT1A receptor. Cell Metab 9:403-405.
38. Mueller BK, Mack H, Teusch N. 2005. Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov 4:387-398.
39. Muñoz A, Rey P, Guerra MJ, Mendez-Alvarez E, Soto-Otero R, Labandeira-Garcia JL. 2006. Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism. Neuropharmacology 51:112-120.
40. Nakagawa O, Fujisawa K, Ishizaki T, Saito Y, Nakao K, Narumiya S. 1996. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett 392:189-193.
41. Ohtsu H, Suzuki H, Nakashima H, Dhobale S, Frank GD, Motley ED, Eguchi S. 2006. Angiotensin II signal transduction through small GTP-binding proteins: Mechanism and significance in vascular smooth muscle cells. Hypertension 48:534-540.
42. Olson MF. 2008. Applications for ROCK kinase inhibition. Curr Opin Cell Biol 20:242-248.
43. Pan Q, Yang XH, Cheng YX. 2009. Angiotensin II stimulates MCP-1 production in rat glomerular endothelial cells via NAD(P)H oxidase-dependent nuclear factor-kappa B signaling. Braz J Med Biol Res 42:531-536.
44. Paxinos G, Watson C. 1986. The rat brain in stereotaxic coordinates. New York: Academic Press.
45. Peterson LJ, Flood PM. 2012. Oxidative stress and microglial cells in Parkinson's disease. Mediators Inflamm 2012:401264.
46. Philippens IH, Wubben JA, Finsen B, 't Hart BA. 2013. Oral treatment with the NADPH oxidase antagonist apocynin mitigates clinical and pathological features of parkinsonism in the MPTP marmoset model. J Neuroimmune Pharmacol 8:715-726.
47. Qin L, Liu Y, Hong JS, Crews FT. 2013. NADPH oxidase and aging drive microglial activation, oxidative stress, and dopaminergic neurodegeneration following systemic LPS administration. Glia 61:855-868.
48. Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS, Knapp DJ, Crews FT. 2007. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 55:453-462.
49. Qin L, Liu Y, Wang T, Wei SJ, Block ML, Wilson B, Liu B, Hong JS. 2004. NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. J Biol Chem 279:1415-1421.
50. Ray R, Shah AM. 2005. NADPH oxidase and endothelial cell function. Clin Sci (Lond) 109:217-226.
51. Re RN. 2004. Tissue renin angiotensin systems. Med Clin North Am 88:19-38.
52. Rey P, Lopez-Real A, Sanchez-Iglesias S, Muñoz A, Soto-Otero R, Labandeira-Garcia JL. 2007. Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons. Neurobiol Aging 28:555-567.
53. Righi M, Mori L, De Libero G, Sironi M, Biondi A, Mantovani A, Donini SD, Ricciardi-Castagnoli P. 1989. Monokine production by microglial cell clones. Eur J Immunol 19:1443-1448.
54. Rodriguez-Pallares J, Parga JA, Joglar B, Guerra MJ, Labandeira-Garcia JL. 2012. Mitochondrial ATP-sensitive potassium channels enhance angiotensin-induced oxidative damage and dopaminergic neuron degeneration. Relevance for aging-associated susceptibility to Parkinson's disease. Age (Dordr) 34:863-880.
55. Rodriguez-Pallares J, Rey P, Parga JA, Muñoz A, Guerra MJ, Labandeira-Garcia JL. 2008. Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. Neurobiol Dis 31:58-73.
56. Rodriguez-Pallares J, Parga JA, Muñoz A, Rey P, Guerra MJ, Labandeira-Garcia JL. 2007. Mechanism of 6-hydroxydopamine neurotoxicity: The role of NADPH oxidase and microglial activation in 6-hydroxydopamine-induced degeneration of dopaminergic neurons. J Neurochem 103:145-156.
57. Rodriguez-Perez AI, Dominguez-Meijide A, Lanciego JL, Guerra MJ, Labandeira-Garcia JL. 2013a. Dopaminergic degeneration is enhanced by chronic brain hypoperfusion and inhibited by angiotensin receptor blockage. Age 35:1675-1690.
58. Rodriguez-Perez AI, Dominguez-Meijide A, Lanciego JL, Guerra MJ, Labandeira-Garcia JL. 2013b. Inhibition of Rho kinase mediates the neuroprotective effects of estrogen in the MPTP model of Parkinson's disease. Neurobiol Dis 58:209-219.
59. Rodriguez-Perez AI, Valenzuela R, Villar-Cheda B, Guerra MJ, Labandeira-Garcia JL. 2012. Different dopaminergic of hormonal replacement therapy in young and aged menopausal rats. Role of the brain angiotensin system. Brain 135:124-138.
60. Rojo AI, McBean G, Cindric M, Egea J, López MG, Rada P, Zarkovic N, Cuadrado A. 2014. Redox control of microglial function: Molecular mechanisms and functional significance. Antioxid Redox Signal 2014. doi:10.1089/ars.2013.5745.
61. Rueckschloss U, Quinn MT, Holtz J, Morawietz H. 2002. Dose-dependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: Protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease. Arterioscler Thromb Vasc Biol 22:1845-1851.
62. Schreck R, Rieber P, Baeuerle PA. 1991. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J 10:2247-2258.
63. Senokuchi T, Matsumura T, Sakai M, Yano M, Taguchi T, Matsuo T, Sonoda K, Kukidome D, Imoto K, Nishikawa T, Kim-Mitsuyama S, Takuwa Y, Araki E. 2005. Statins suppress oxidized low density lipoprotein-induced macrophage proliferation by inactivation of the small G protein-p38 MAPK pathway. J Biol Chem 280:6627-6633.
64. Sheikh AM, Nagai A, Ryu JK, McLarnon JG, Kim SU, Masuda J. 2009. Lysophosphatidylcholine induces glial cell activation: Role of rho kinase. Glia 57:898-907.
65. Song Y, Chen X, Wang LY, Gao W, Zhu MJ. 2013. Rho kinase inhibitor fasudil protects against β-amyloid-induced hippocampal neurodegeneration in rats. CNS Neurosci Ther 19:603-610.
66. Tolleson, C.M., Fang, J.Y. 2013. Advances in the mechanisms of Parkinson's disease. Disco Med 15:61-66.
67. Tönges L, Frank T, Tatenhorst L, Saal KA, Koch JC, Szego ÉM, Bähr M, Weishaupt JH, Lingor P. 2012. Inhibition of rho-kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson's disease. Brain 135:3355-3370.
68. Tönges L, Günther R, Suhr M, Jansen J, Balck A, Saal KA, Barski E, Nientied T, Götz AA, Koch JC, Mueller BK, Weishaupt JH, Sereda MW, Hanisch UK, Bähr M, Lingor P. 2014. Rho kinase inhibition modulates microglia activation and improves survival in a model of amyotrophic lateral sclerosis. Glia 62:217-232.
69. Touyz RM, Chen X, Tabet F, Yao G, He G, Quinn MT, Pagano PJ, Schiffrin EL. 2002. Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries, regulation by angiotensin II. Circ Res 14:1205-1213.
70. Tsai YR, Wang YJ, Lee MR, Hsu MF, Wang JP. 2013. p38 Mitogen-activated protein kinase and extracellular signal-regulated kinase signaling pathways are not essential regulators of formyl peptide-stimulated p47(phox) activation in neutrophils. Eur J Pharmacol 701:96-105.
71. Villar-Cheda B, Dominguez-Meijide A, Joglar B, Rodriguez-Perez AI, Guerra MJ, Labandeira-Garcia JL. 2012a. Involvement of microglial RhoA/Rho-kinase pathway activation in the dopaminergic neuron death. Role of angiotensin via angiotensin type 1 receptors. Neurobiol Dis 47:268-279.
72. Villar-Cheda B, Dominguez-Meijide A, Valenzuela R, Granado N, Moratalla R, Labandeira-Garcia JL. 2014. Aging-related dysregulation of dopamine and angiotensin receptor interaction. Neurobiol Aging 35:1726-38.
73. Villar-Cheda B, Valenzuela R, Rodriguez-Perez AI, Guerra MJ, Labandeira-Garcia JL. 2012b. Aging-related changes in the nigral angiotensin system enhances proinflammatory and pro-oxidative markers and 6-OHDA-induced dopaminergic degeneration. Neurobiol Aging 33:204.e1-11.
74. Wang XJ, Zhang S, Yan ZQ, Zhao YX, Zhou HY, Wang Y, Lu GQ, Zhang JD. 2011. Impaired CD200-CD200R-mediated microglia silencing enhances midbrain dopaminergic neurodegeneration: Roles of aging, superoxide, NADPH oxidase, and p38 MAPK. Free Radic Biol Med 50:1094-1106.
75. Wright JW, Harding JW. 2012. Importance of the brain Angiotensin system in Parkinson's disease. Parkinsons Dis 2012 :860923.
76. Wright JW, Kawas LH, Harding JW. 2013. A role for the brain RAS in Alzheimer's and Parkinson's diseases. Front Endocrinol 4:158.
77. Wu D, Teisman P, Tieu K, Vila M, Jackson-Lewis V, Ischiropoulos H, Przedborski S. 2003. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci USA 100:6145-6150.
78. Wu J, Li J, Hu H, Liu P, Fang Y, Wu D. 2012. Rho-kinase inhibitor, fasudil, prevents neuronal apoptosis via the Akt activation and PTEN inactivation in the ischemic penumbra of rat brain. Cell Mol Neurobiol 32:1187-1197.
79. Yamamori T, Inanami O, Sumimoto H, Akasaki T, Nagahata H, Kuwabara M. 2002. Relationship between p38 mitogen-activated protein kinase and small GTPase Rac for the activation of NADPH oxidase in bovine neutrophils. Biochem Biophys Res Commun 293:1571-1578.
80. Yan J, Zhou X, Guo JJ, Mao L, Wang YJ, Sun J, Sun LX, Zhang LY, Zhou XF, Liao H. 2012. Nogo-66 inhibits adhesion and migration of microglia via GTPase Rho pathway in vitro. J. Neurochem 120:721-731.
81. Zawada WM, Banninger GP, Thornton J, Marriott B, Cantu D, Rachubinski AL, Das M, Griffin WS, Jones SM. 2011. Generation of reactive oxygen species in 1-methyl-4-phenylpyridinium (MPP+) treated dopaminergic neurons occurs as an NADPH oxidase-dependent two-wave cascade. J Neuroinflammation 8:129.
82. Zhang Y, Gu X, Yuan X. 2007. Phenylalanine activates the mitochondria-mediated apoptosis through the RhoA/Rho-associated kinase pathway in cortical neurons. Eur J Neurosci 25:1341-1348.
83. Zhang H, Li Y, Yu J, Guo M, Meng J, Liu C, Xie Y, Feng L, Xiao B, Ma C. 2013. Rho kinase inhibitor fasudil regulates microglia polarization and function. Neuroimmunomodulation 20:313-22.